SOLUTRANS
26.10.2021 08:02:12 CEST | Business Wire | Press release
SOLUTRANS , the global hub for heavy and light commercial vehicles, will hold its 16th edition from 16 to 20 November 2021 in Lyon Eurexpo (France). Nearly 60,000 professionals, 1,000 exhibitors and brands are expected to attend this international event focusing on economic recovery and innovation, certified by the OICA (International Organization of Motor Vehicle Manufacturers).
This edition will showcase two major additions. Firstly, a "SOLUTRANS 4.0" hall dedicated to innovation for transport professionals. Secondly, the chance for professionals from all over the world to take part in the show remotely via the SOLUTRANS DIGITAL SHOW.
HGV manufacturers will be in attendance
The leading HGV manufacturers, such as DAF, IVECO, MAN, Mercedes, Renault Trucks, SCANIA and VOLVO will be exhibiting at SOLUTRANS. The largest bodywork manufacturers, vehicle fitters and service companies will also be present, as well as new names in the sector such as FORD TRUCKS, IRIZAR and VOLTA TRUCKS, who will be taking part for the first time in France.
SOLUTRANS 4.0, the hall of new technologies
This hall will present disruptive innovations and new names in the sector in all areas, from engineering to industry as well as IT solutions.
The objective of SOLUTRANS 4.0 is to foster the implementation of new solutions to optimize activity and overcome the challenges in the sector: energy transition, artificial intelligence, cybersecurity, recycling, etc.
Innovation gets the green light at SOLUTRANS !
All the innovations will be presented during the various award ceremonies that will take place during the trade show. The I-nnovation Awards have been further enriched this year and include a new prize: the "Digital AWARD". Also, for the fourth consecutive edition, SOLUTRANS will host the International Awards: ITOY, IVOTY, IPUA and TRUCK INNOVATION AWARD. These awards, recognized by the industry as a whole, reward the excellence of manufacturers and showcase the trends in the industrial and urban vehicle sector.
The theme of innovation will also be highlighted during the event via a broad range of conferences covering a variety of topics that respond to the challenges of the sector.
Finally, SOLUTRANS, in partnership with TotalEnergies, will be offering a new, completely redesigned and larger testing area to meet the needs of visitors and manufacturers of heavy and light commercial vehicles. The track has also been extended and re-designed with a 25 km semi-urban route to allow professionals to test the vehicles around the park.
SOLUTRANS DIGITAL SHOW: unlimited online access to the trade show
The SOLUTRANS DIGITAL SHOW, the virtual edition of the physical exhibition, will offer registered visitors, wherever they are located in the world, an interactive space where they can visit exhibitors' stands, contact their representatives and discover their new products… it’s all just click away! Two weeks before the actual trade show, registered visitors will be able to start making appointments with exhibitors and take advantage of the three additional days of opening to consult an exhibitor's offer online, thus giving them a chance to contact businesses that they wouldn’t have had time to meet during the physical edition of the trade show. They will also have access to conferences and other events, which will be broadcast live.
Discover the whole program of the SOLUTRANS 2021 trade show on solutrans.eu
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom